Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.

MLA

Patel, Mikin V., et al. “Transarterial Therapies in Patients with Hepatocellular Carcinoma Eligible for Transarterial Embolization: A US Cost-Effectiveness Analysis.” Journal of Medical Economics, vol. 26, no. 1, Jan. 2023, pp. 1061–71. EBSCOhost, https://doi.org/10.1080/13696998.2023.2248840.

APA

Patel, M. V., Davies, H., Williams, A. O., Bromilow, T., Baker, H., Mealing, S., Holmes, H., Anderson, N., & Ahmed, O. (2023). Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis. Journal of Medical Economics, 26(1), 1061–1071. https://doi.org/10.1080/13696998.2023.2248840

Chicago

Patel, Mikin V., Heather Davies, Abimbola O. Williams, Tom Bromilow, Hannah Baker, Stuart Mealing, Hayden Holmes, Nicholas Anderson, and Osman Ahmed. 2023. “Transarterial Therapies in Patients with Hepatocellular Carcinoma Eligible for Transarterial Embolization: A US Cost-Effectiveness Analysis.” Journal of Medical Economics 26 (1): 1061–71. doi:10.1080/13696998.2023.2248840.